Abstract
Acne vulgaris is a chronic inflammatory skin disease. Key events that contribute to acne pathogenesis include hyperseborrhea, hyperkeratinization of the pilosebaceous follicle, the loss of diversity of Cutibacterium acnes (C. acnes) phylotypes, inflammation, and exposome (external factors such as nutrition, pollutants, lifestyle). Acneiform eruptions that may need to be differentiated from acne are: acne cosmetica, perioral dermatitis, drug-induced acneiform eruptions, and rosacea. The management of acne is based on the clinical classification depending on the predominant lesions, severity and presence of scarring, and further depends on the psychological impact of acne, the age, and medical history of the patient. Treatments are usually combinations of topical agents, such as retinoids, azelaic acid, benzoyl peroxide, antibiotics and fixed-dose combination formulations, and/or systemic agents, such as antibiotics, zinc, isotretinoin, and for females only, hormonal therapies. Furthermore, the recommendations of the current European guidelines are discussed and therapeutic algorithms for the treatment of acne according to age group are presented.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Abdel Fattah NS, Darwish YW. In vitro antibiotic susceptibility patterns of Propionibacterium acnes isolated from acne patients: an Egyptian university hospital-based study. J Eur Acad Dermatol Venereol. 2013;27(12):1546–51.
Albuquerque RG, Rocha MA, Bagatin E, Tufik S, Andersen ML. Could adult female acne be associated with modern life? Arch Dermatol Res. 2014;306(8):683–8.
Antoniou C, Dessinioti C, Stratigos AJ, Katsambas AD. Clinical and therapeutic approach to childhood acne: an update. Pediatr Dermatol. 2009;26(4):373–80.
Aubert J, Piwnica D, Bertino B, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-gamma agonist trifarotene. Br J Dermatol. 2018;179(2):442–56.
Blume-Peytavi U, Fowler J, Kemeny L, et al. Long-term safety and efficacy of trifarotene 50 mug/g cream, a first-in-class RAR-gamma selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166–73.
Carmina et al. Female adult acne and androgen excess: a report from the multidisciplinary androgen excess and PCOS committee. J Endocr Soc. 2022;6:bvac003.
Carlavan I, Bertino B, Rivier M, et al. Atrophic scar formation in patients with acne involves long-acting immune responses with plasma cells and alteration of sebaceous glands. Br J Dermatol. 2018;179(4):906–17.
Chen W, Obermayer-Pietsch B, Hong JB, et al. Acne-associated syndromes: models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol. 2011;25(6):637–46.
Chernyshov PV, Zouboulis CC, Tomas-Aragones L, et al. Quality of life measurement in acne. Position paper of the European academy of dermatology and venereology task forces on quality of life and patient oriented outcomes and acne, rosacea and hidradenitis Suppurativa. J Eur Acad Dermatol Venereol. 2018;32(2):194–208.
Claudel JP, Auffret N, Leccia MT, Poli F, Dreno B. Acne and nutrition: hypotheses, myths and facts. J Eur Acad Dermatol Venereol. 2018;32(10):1631–7.
Claudel JP, Auffret N, Leccia MT, Poli F, Corvec S, Dreno B. Staphylococcus epidermidis: a potential new player in the physiopathology of acne? Dermatology. 2019;235(4):287–94.
Collier CN, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58(1):56–9.
Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J. 1979;1(6171):1109–10.
Dagnelie MA, Corvec S, Saint-Jean M, et al. Decrease in diversity of Propionibacterium acnes phylotypes in patients with severe acne on the Back. Acta Derm Venereol. 2018;98(2):262–7.
Dagnelie MA, Corvec S, Saint-Jean M, Nguyen JM, Khammari A, Dreno B. Cutibacterium acnes phylotypes diversity loss: a trigger for skin inflammatory process. J Eur Acad Dermatol Venereol. 2019;33(12):2340–8.
Del Rosso JQ et al. Management of truncal acne with oralsarecycline: Pooled results from two phase-3 clinical trials. J Drugs Dermtol. 2021;20:634–40.
Dessinioti C, Katsambas AD. The role of Propionibacterium acnes in acne pathogenesis: facts and controversies. Clin Dermatol. 2010;28(1):2–7.
Dessinioti C, Katsambas A. Difficult and rare forms of acne. Clin Dermatol. 2017a;35(2):138–46.
Dessinioti C, Katsambas A. Propionibacterium acnes and antimicrobial resistance in acne. Clin Dermatol. 2017b;35(2):163–7.
Dessinioti C, Antoniou C, Katsambas A. Acneiform eruptions. Clin Dermatol. 2014;32(1):24–34.
Dessinioti C, Zisimou C, Platsidaki E, Katsambas A, Antoniou C. A cross-sectional study of clinical factors associated with acne facial scarring in patients with active acne. J Eur Acad Dermatol Venereol. 2018a;32(6):e212–4.
Dessinioti C, Platsidaki E, Zisimou C, Tzanetakou V, Katsambas A, Antoniou C. A cross-sectional study of the perceptions about triggering factors in acne patients. J Eur Acad Dermatol Venereol. 2018b;32(4):e137–9.
Dessinioti C, Zouboulis CC, Bettoli V, Rigopoulos D. Comparison of guidelines and consensus articles on the management of patients with acne with oral isotretinoin. J Eur Acad Dermatol Venereol. 2020;34:2229.
Dreno B. Treatment of adult female acne: a new challenge. J Eur Acad Dermatol Venereol. 2015;29(Suppl 5):14–9.
Dreno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31(Suppl 5):8–12.
Dreno B, Layton A, Zouboulis CC, et al. Adult female acne: a new paradigm. J Eur Acad Dermatol Venereol. 2013;27(9):1063–70.
Dreno B, Bagatin E, Blume-Peytavi U, Rocha M, Gollnick H. Female type of adult acne: physiological and psychological considerations and management. J Dtsch Dermatol Ges. 2018a;16(10):1185–94.
Dreno B, Bettoli V, Araviiskaia E, Sanchez Viera M, Bouloc A. The influence of exposome on acne. J Eur Acad Dermatol Venereol. 2018b;32(5):812–9.
Dreno B, Bordet C, Seite S, Taieb C, Registre AD. Acne relapses: impact on quality of life and productivity. J Eur Acad Dermatol Venereol. 2019;33(5):937–43.
Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013;131(Suppl 3):S163–86.
Eichenfield et al. J Am Acad Dermatol. 2020;83:477–85.
Fitz-Gibbon S, Tomida S, Chiu BH, et al. Propionibacterium acnes strain populations in the human skin microbiome associated with acne. J Invest Dermatol. 2013;133(9):2152–60.
Gonzalez R, Welsh O, Ocampo J, et al. In vitro antimicrobial susceptibility of Propionibacterium acnes isolated from acne patients in northern Mexico. Int J Dermatol. 2010;49(9):1003–7.
Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41(4):577–80.
Isvy-Joubert A, Nguyen JM, Gaultier A, et al. Adult female acne treated with spironolactone: a retrospective data review of 70 cases. Eur J Dermatol. 2017;27(4):393–8.
Hebert et al. Efficacy and safety of topical clascoterone cream, 1% for treatment in patients with facial acne. JAMA Dermatol. 2020;156:621–30.
Jacob CI, Dover JS, Kaminer MS. Acne scarring: a classification system and review of treatment options. J Am Acad Dermatol. 2001;45(1):109–17.
Kim JE, Park AY, Lee SY, Park YL, Whang KU, Kim HJ. Comparison of the efficacy of azithromycin versus doxycycline in acne vulgaris: a meta-analysis of randomized controlled trials. Ann Dermatol. 2018;30(4):417–26.
Layton AM, Henderson CA, Cunliffe WJ. A clinical evaluation of acne scarring and its incidence. Clin Exp Dermatol. 1994;19(4):303–8.
Layton AM, Dreno B, Gollnick HP, Zouboulis CC. A review of the European directive for prescribing systemic isotretinoin for acne vulgaris. J Eur Acad Dermatol Venereol. 2006;20(7):773–6.
Moradi Tuchayi S, Makrantonaki E, Ganceviciene R, Dessinioti C, Feldman SR, Zouboulis CC. Acne vulgaris. Nat Rev Dis Primers. 2015;1:15029.
Nakase K, Hayashi N, Akiyama Y, Aoki S, Noguchi N. Antimicrobial susceptibility and phylogenetic analysis of Propionibacterium acnes isolated from acne patients in Japan between 2013 and 2015. J Dermatol. 2017;44(11):1248–54.
Nast A, Dreno B, Bettoli V, et al. European evidence-based (S3) guideline for the treatment of acne—update 2016—short version. J Eur Acad Dermatol Venereol. 2016;30(8):1261–8.
O’Neill AM, Nakatsuji T, Hayachi A, et al. Identification of a human skin commensal bacterium that selectively kills Cutibacterium acnes. J Invest Dermatol. 2020;140(8):1619–28.
Paugam C, Corvec S, Saint-Jean M, et al. Propionibacterium acnes phylotypes and acne severity: an observational prospective study. J Eur Acad Dermatol Venereol. 2017;31(9):e398–9.
Platsidaki E, Dessinioti C. Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Res. 2018;7:1953.
Poli F, Dreno B, Verschoore M. An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol. 2001;15(6):541–5.
Ross JI, Snelling AM, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol. 2003;148(3):467–78.
Saint-Jean M, Corvec S, Nguyen JM, et al. Adult acne in women is not associated with a specific type of Cutibacterium acnes. J Am Acad Dermatol. 2019;81(3):851–2.
Scholz CFP, Kilian M. The natural history of cutaneous propionibacteria, and reclassification of selected species within the genus Propionibacterium to the proposed novel genera Acidipropionibacterium gen. nov., Cutibacterium gen. nov. and Pseudopropionibacterium gen. nov. Int J Syst Evol Microbiol. 2016;66(11):4422–32.
Soon CWM, Pincus LB, Ai WZ, McCalmont TH. Acneiform presentation of primary cutaneous follicle center lymphoma. J Am Acad Dermatol. 2011;65(4):887–9.
Tan J, Kang S, Leyden J. Prevalence and risk factors of acne scarring among patients consulting dermatologists in the USA. J Drugs Dermatol. 2017;16(2):97–102.
Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 mug/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–9.
Thiboutot DM, Dreno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the global alliance to improve outcomes in acne. J Am Acad Dermatol. 2018;78(2 Suppl 1):S1–S23 e21.
Xu J et al. Management of acne vulgaris: summary of NICE guidance. BMJ. 2021;374:n1800.
Xia et al. JAMA Dermatol. 2022;158:942–48.
Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973 e933.
Zhu T, Zhu W, Wang Q, et al. Antibiotic susceptibility of Propionibacterium acnes isolated from patients with acne in a public hospital in Southwest China: prospective cross-sectional study. BMJ Open. 2019;9(2):e022938.
Zouboulis CC, Dessinioti C, Tsatsou F, Gollnick HPM. Anti-acne drugs in phase 1 and 2 clinical trials. Expert Opin Investig Drugs. 2017;26(7):813–23.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Dessinioti, C., Dreno, B. (2023). Acne. In: Katsambas, A.D., Lotti, T.M., Dessinioti, C., D'Erme, A.M. (eds) European Handbook of Dermatological Treatments. Springer, Cham. https://doi.org/10.1007/978-3-031-15130-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-031-15130-9_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-15129-3
Online ISBN: 978-3-031-15130-9
eBook Packages: MedicineMedicine (R0)